Latest Articles

Researchers are working tirelessly to design new drugs and repurpose existing drugs against the novel coronavirus SARS-CoV-2.

Oral vaccines are less immunogenic when administered in low-income countries compared to high-income countries. Several factors can contribute to this reduced efficacy, including enteric dysfunction. Technology Networks spoke with Dr. Timothy Hand, to learn about his research in this area.

This article explores how immunopeptidomics can be used to accurately determine HLA-II peptide-binding motifs and its recent utilization in exploring peptide presentation in response to SARS-CoV-2, demonstrating the capability of this technique to reveal additional insights to support therapeutic development.

Technology Networks is committed to keeping you updated with the latest research in this space. Here, you'll find a curation of our latest COVID-19 vaccine-related content.

In this honest account, science writer Leo Bear-McGuinness shares what it's like to live with long COVID as a "long-hauler", and explores how the condition has awakened an urgency in post-viral research.

What research has been conducted that explores menstrual cycles throughout the COVID-19 global pandemic? How scientifically sound are these studies, and what can they tell us? In this interview, we spoke with Dr. Gemma Sharp and Dr. Kayleigh Easey to learn about research gaps and opportunities in this space.

In this article, we highlight advances in the field that have been instrumental to the development of microphysiological systems, as well as key applications and future opportunities.

Technology Networks spoke to Hiroshi Kiyono, DDS, PhD, from the Institute of Medical Science at the University of Tokyo who is currently also affiliated with Chiba University and University of California, San Diego, to find out more about MucoRice-CTB, a room-temperature stable oral vaccine being developed using genetically modified rice plants.

Dr. Yi Shi, assistant professor in the department of cell biology at the University of Pittsburgh and colleagues are exploring the potential of nanobodies as a treatment for COVID-19. The team recently published findings from preclinical studies on the use of a nanobody called Pittsburgh inhalable Nanobody-21 (PiN-21) that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein.

How do humans tap into microalgae’s “life experience” to acquire valuable knowledge? To do so, we must learn to speak their “language” and translate that information into useful applications for society and its industries. Amazingly, recent strides in microalgae biotechnology, synthetic biology, and biomanufacturing are making that possible.